Showing results (121-130 of 153) with videos related to

Sort By:
Pageof 16
American Journal of Respiratory and Critical Care Medicine|August 7, 2015
Multicenter Comparison of Lung and Oral Microbiomes of HIV-infected and HIV-uninfected IndividualsJames M Beck, Patrick D Schloss, Arvind Venkataraman, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 6, 2023
HIV post-treatment controllers have distinct immunological and virological featuresBehzad Etemad, Xiaoming Sun, Yijia Li, et al.
The Lancet. HIV|May 1, 2024
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trialIan Frank, Shuying S Li, Nicole Grunenberg, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal AntibodySrilatha Edupuganti, Nyaradzo Mgodi, Shelly T Karuna, et al.
The Journal of Infectious Diseases|November 5, 2016
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)Roy M Gulick, Timothy J Wilkin, Ying Q Chen, et al.
The New England Journal of Medicine|October 9, 2013
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccineScott M Hammer, Magdalena E Sobieszczyk, Holly Janes, et al.
Annals of Internal Medicine|August 23, 2017
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized TrialRoy M Gulick, Timothy J Wilkin, Ying Q Chen, et al.
Open Forum Infectious Diseases|July 23, 2015
First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)Jonathan D Fuchs, Ian Frank, Marnie L Elizaga, et al.
Vaccine|March 22, 2026
DNA electroporation of HIV Env elicits robust T cell responses and memory B cell responses with muted serum antibody levels that can be boosted with recombinant proteinStephen C De Rosa, Ronnie M Gravett, William O Hahn, et al.
The Journal of Infectious Diseases|October 5, 2023
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120Zvavahera Mike Chirenje, Fatima Laher, One Dintwe, et al.
Pageof 16